Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.50 |
| ▸ | SQLE | Q14534 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11524833 | 1.00 | ALOX15 (1.00) | ALOX15KMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL1586712 | 1.00 | ALOX15 (1.00) | ALOX15KMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL11518352 | 1.00 | ALOX15 (1.00) | ALOX15KMT2AMAPTMEN1CYP3A4 | |
| Nerolidol SCHEMBL7551916 | 1.00 | ALOX15 (1.00) | ALOX15KMT2AMAPTMEN1CYP3A4 | |
| Nerolidol SCHEMBL6883271 | 1.00 | ALOX15 (1.00) | ALOX15KMT2AMAPTMEN1CYP3A4 | |
| Nerolidiol SCHEMBL6514677 | 1.00 | ALOX15 (1.00) | ALOX15KMT2AMAPTMEN1CYP3A4 | |
| Nerolidol SCHEMBL9064064 | 1.00 | ALOX15 (1.00) | ALOX15KMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL11524835 | 1.00 | ALOX15 (1.00) | ALOX15KMT2AMAPTMEN1CYP3A4 | |
| SCHEMBL249658 | 1.00 | ALOX15 (1.00) | ALOX15KMT2AMAPTMEN1CYP3A4 | |
| Nerolidol SCHEMBL114138 | 1.00 | ALOX15 (1.00) | ALOX15KMT2AMAPTMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10201510-B2 | Compositions and methods for treatment of neurological symptoms associated with alcohol-withdrawal and for convulsive seizure | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2019-02-12 | — | — | US | disclosed |
| EP-2496682-A1 | DELIVERY PARTICLE | The Procter & Gamble Company (US) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011056935-A1 | DELIVERY PARTICLE | THE PROCTER & GAMBLE COMPANY (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20080286209-A1 | Compositions and Methods for Treatment of Neurological Symptoms Associated with Alcohol-Withdrawal and for Consulsive Seizure | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10201510-B2 | Compositions and methods for treatment of neurological symptoms associated with alcohol-withdrawal and for convulsive seizure | ADH1C, ADH1A, CHRNA10 | ALOX15 632/4885KMT2A 1291/4885MAPT 295/4885 |
| US-20080286209-A1 | Compositions and Methods for Treatment of Neurological Symptoms Associated with Alcohol-Withdrawal and for Consulsive Seizure | PNMT, ADH1A, CHRNA10 | ALOX15 1764/4885KMT2A 1287/4885MAPT 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.